" /> " />

Arcturus Therapeutics Earnings Estimate

ARCT Stock  USD 33.77  0.91  2.77%   
The next projected EPS of Arcturus Therapeutics is estimated to be -1.05 with future projections ranging from a low of -1.71 to a high of -0.1. Arcturus Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.12. Please be aware that the consensus of earnings estimates for Arcturus Therapeutics Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Arcturus Therapeutics is projected to generate -1.05 in earnings per share on the 31st of March 2024. Arcturus Therapeutics earnings estimates module stress-tests analyst consensus about projected Arcturus Therapeutics Holdings EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Arcturus Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Arcturus Therapeutics' earnings estimates, investors can diagnose different trends across Arcturus Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Arcturus Therapeutics' Gross Profit is comparatively stable compared to the past year. Gross Profit Margin is likely to gain to 1.03 in 2024, whereas Pretax Profit Margin is likely to drop (0.19) in 2024.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Arcturus Therapeutics Earnings Estimation Breakdown

The calculation of Arcturus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Arcturus Therapeutics is estimated to be -1.05 with the future projection ranging from a low of -1.71 to a high of -0.1. Please be aware that this consensus of annual earnings estimates for Arcturus Therapeutics Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.32
-1.71
Lowest
Expected EPS
-1.05
-0.1
Highest

Arcturus Therapeutics Earnings Projection Consensus

Suppose the current estimates of Arcturus Therapeutics' value are higher than the current market price of the Arcturus Therapeutics stock. In this case, investors may conclude that Arcturus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Arcturus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2024Current EPS (TTM)
31.78%
-0.32
-1.05
-1.12

Arcturus Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Arcturus Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Arcturus Therapeutics Holdings predict the company's earnings will be in the future. The higher the earnings per share of Arcturus Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Arcturus Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Arcturus Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Arcturus Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Arcturus Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Arcturus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-07
2023-12-31-0.99-0.320.6767 
2023-11-14
2023-09-30-1.69-0.611.0863 
2023-08-07
2023-06-30-0.21-1.98-1.77842 
2023-05-09
2023-03-310.061.871.813016 
2023-03-28
2022-12-310.984.433.45352 
2022-11-09
2022-09-30-1.81-1.330.4826 
2022-08-09
2022-06-30-1.9-0.821.0856 
2022-05-09
2022-03-31-1.44-1.94-0.534 
2022-02-28
2021-12-31-1.72-1.470.2514 
2021-11-08
2021-09-30-1.59-2.05-0.4628 
2021-08-09
2021-06-30-2.15-2.070.08
2021-05-10
2021-03-31-1.25-2.15-0.972 
2021-03-01
2020-12-31-0.88-1.25-0.3742 
2020-11-09
2020-09-30-0.49-0.92-0.4387 
2020-08-10
2020-06-30-0.55-0.550.0
2020-05-07
2020-03-31-0.61-0.67-0.06
2020-03-11
2019-12-31-0.53-0.76-0.2343 
2019-11-07
2019-09-30-0.36-0.56-0.255 
2019-08-15
2019-06-30-0.63-0.070.5688 
2019-05-13
2019-03-31-0.58-0.65-0.0712 
2019-03-18
2018-12-31-0.48-0.080.483 
2018-11-07
2018-09-30-0.56-0.420.1425 
2018-09-28
2018-06-30-0.7-0.99-0.2941 
2018-05-14
2018-03-31-0.46-1.08-0.62134 
2018-02-15
2017-12-31-0.46-1.08-0.62134 
2017-11-09
2017-09-30-2.66-0.71.9673 
2017-08-11
2017-06-30-0.94-0.910.03
2017-05-30
2017-03-31-1.26-0.910.3527 
2017-02-15
2016-12-31-1.9-1.540.3618 
2016-11-15
2016-09-30-1.8-1.96-0.16
2016-08-30
2016-06-30-1.53-1.470.06
2016-05-16
2016-03-31-1.51-1.260.2516 
2016-02-17
2015-12-31-1.68-1.40.2816 
2015-11-12
2015-09-30-2.17-1.40.7735 
2015-08-13
2015-06-30-2.01-1.680.3316 
2015-05-06
2015-03-31-2.01-1.820.19
2015-02-12
2014-12-31-4.2-3.50.716 
2014-11-17
2014-09-30-3.89-5.39-1.538 
2014-08-11
2014-06-30-3.71-3.99-0.28
2014-05-15
2014-03-31-2.85-3.71-0.8630 
2014-02-13
2013-12-31-2.2-3.15-0.9543 
2013-11-07
2013-09-30-0.63-1.96-1.33211 
2013-08-06
2013-06-30-0.42-0.420.0

About Arcturus Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Arcturus Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Arcturus Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Arcturus Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings-367.9 M-349.5 M
Retained Earnings Total Equity-312.7 M-297.1 M
Price Earnings Ratio(28.24)(26.83)
Price Earnings To Growth Ratio 0.07  0.06 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcturus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcturus Therapeutics' short interest history, or implied volatility extrapolated from Arcturus Therapeutics options trading.

Pair Trading with Arcturus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Arcturus Stock

  0.64VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.45MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.41MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.
The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Arcturus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Arcturus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Arcturus Therapeutics Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Arcturus Therapeutics Holdings Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Arcturus Stock analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
CEOs Directory
Screen CEOs from public companies around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bonds Directory
Find actively traded corporate debentures issued by US companies
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stocks Directory
Find actively traded stocks across global markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
6.264
Quarterly Revenue Growth
(0.81)
Return On Assets
(0.11)
Return On Equity
(0.11)
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.